Podcast: Getting Your Radiology Solution Out There
Paul Chang, MD, offers some advice and warns of a few pitfalls radiology professionals face when getting their home-grown IT tools into the market.
[[{"type":"media","view_mode":"media_crop","fid":"8023","attributes":{"alt":"","class":"media-image media-image-left","id":"media_crop_5428327812734","media_crop_h":"0","media_crop_image_style":"-1","media_crop_instance":"208","media_crop_rotate":"0","media_crop_scale_h":"0","media_crop_scale_w":"0","media_crop_w":"0","media_crop_x":"0","media_crop_y":"0","style":"margin: 5px; float: left;","title":" ","typeof":"foaf:Image"}}]]Radiology clinicians and researchers know the requirements of their work flow better than any vendor or marketing survey - so many are developing their own software. Today, it’s easier than ever to develop IT solutions, but there can be a lot of obstacles, says Paul Chang, MD, FSIIM, professor and vice chairman of radiology informatics at the University of Chicago School of Medicine.
In this podcast, the second in a two-part series, Chang previews some of the advice and guidance he’ll be giving at SIIM 2012 on how to get your solution into the market.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
